Clinical Trials Browser

Colorectal Neoplasms

NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Phase 2 Recruiting

197 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07227636 2026-02-06

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

Phase 2 Recruiting

284 enrolled

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT06268015 2026-02-05

BBOpCo

Phase 2 Active not recruiting

16 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT06589440 2026-01-15

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Phase 2 Recruiting

70 enrolled

Gastrointestinal

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

NCT06251973 2025-12-02

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Phase 2 Recruiting

37 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT06843434 2025-12-02

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Microsatellite Stable Rectal Carcinoma

NCT05608044 2025-09-04

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Phase 2 Active not recruiting

234 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06843551 2025-08-14

EMPIRE

Phase 2 Recruiting

20 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05571293 2025-07-30

NEST-1

Phase 2 Suspended

36 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Colorectal Neoplasms

NCT06780787 2025-06-26

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Phase 2 Recruiting

26 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06575725 2024-11-21

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05638698 2024-09-23

TESLA

Phase 2 Active not recruiting

24 enrolled

Gastrointestinal

Pancreatic Neoplasms

Clinical Trials

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

BBOpCo

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

EMPIRE

NEST-1

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

TESLA